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Abstract
Introduction: Previous studies have implicated a strong link between circulating plasma resistin and coronary artery disease (CAD). The aim of this 
study was to evaluate the differences in peripheral blood mononuclear cells (PBMC) resistin mRNA and its plasma protein concentrations between 
the patients with CAD of different clinical severity.
Material and methods: This study included 33 healthy subjects as the control group (CG) and 77 patients requiring coronary angiography. Of the 
latter 30 was CAD negative whereas 47 were CAD positive [18 with stable angina pectoris (SAP) and 29 with acute coronary syndrome (ACS)]. Circu-
lating resistin was measured by ELISA; PBMC resistin mRNA was determined by real-time PCR. 
Results: Resistin protein was significantly higher in the ACS group compared to the CG (P = 0.001) and the CAD negative group (P = 0.018). Resistin 
mRNA expression did not vary across the study groups, despite the positive correlation seen with plasma resistin (ρ = 0.305, P = 0.008). In patients, 
plasma resistin and PBMC resistin mRNA negatively correlated with HDL-C (ρ = -0.404, P < 0.001 and ρ = -0.257, P = 0.032, respectively). Further-
more, the highest plasma resistin tertile showed the lowest HDL-C (P = 0.006). Plasma resistin was positively associated with serum creatinine (ρ = 
0.353, P = 0.002).
Conclusion: Significant increase of plasma resistin in patients with ACS compared to CG and CAD negative patients was observed. Despite no chan-
ge in PBMC resistin mRNA in different disease conditions a positive association between resistin mRNA and resistin plasma protein was evident. Both 
plasma resistin and PBMC resistin mRNA were negatively associated with plasma HDL-C, and plasma resistin positively with serum creatinine.  
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Coronary artery disease (CAD) is one of the major 
causes of morbidity and loss of quality of life 
across the globe. The pathogenesis of CAD lays in 
the development of dyslipidemia, increased proin-
flammatory processes and consequently athero-
sclerosis evolvement and progression (1). Compli-
cations of CAD vary depending on the extent and 
perhaps more importantly on the stability of ath-
erosclerotic lesions: from stable conditions, such 
as stabile angina pectoris (SAP) to acute coronary 
syndrome (ACS) which includes unstable angina 
pectoris (UAP) and acute myocardial infarction 
(AMI) (2). 
Resistin, a 12.5 kDa peptide, first discovered in 
mouse white adipose tissue has been linked to in-
sulin resistance and type 2 diabetes development 
in mice (3). However, in humans, that link has been 
by far questioned (4). Human resistin belongs to a 
family of cysteine-rich secretory proteins that in-
clude resistin-like molecules (RELMs) (5). Unlike in 
mice, where it is expressed predominately by adi-
pocytes (3), human resistin is expressed and se-
creted mainly by peripheral blood mononuclear 
cells (PBMCs), macrophages and bone marrow 
cells (6). Human resistin has been shown to have 
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proinflammatory properties and it is involved in 
complex feedback interactions with other proin-
flammatory cytokines such as interleukin 6 (IL-6), 
tumor necrosis factor-alpha (TNF-α) and interleu-
kin 1-beta (IL-1β) (7). Adenylate cyclase-associated 
protein 1 (CAP1 protein), a recently identified bona 
fide receptor for human resistin, is proposed to 
conduct these inflammatory signals, through acti-
vation of adenylate cyclase, and increased produc-
tion of cyclic adenosine monophosphate, which 
activates protein kinase A and NF-κB (nuclear fac-
tor kappa-light-chain-enhancer of activated B 
cells) pathways leading to increased production of 
IL-6, TNF-α and IL-1β (8). 
Resistin exerts many effects contributing to ather-
osclerosis. In vitro experiments have shown that 
resistin leads to decreased expression of nitric ox-
ide synthase in human coronary artery endothelial 
lines (HCAECL) (6), increases monolayer permeabil-
ity of HCAECLs (9), accelerates plaque progression 
by stimulating monocyte infiltration (10), upregu-
lates endothelin-1, vascular cell adhesion molecule 
-1 (VCAM-1), intracellular adhesion molecule-1 
(ICAM-1) and monocyte chemoattractant protein 
(MCP-1) in vascular endothelial cells (6) and in-
creases lipid accumulation in macrophages con-
tributing to foam cell formation (6,11).
Data from clinical studies have revealed an associ-
ation between resistin protein and traditional risk 
factors for atherosclerosis: Inverse correlations 
were observed with protective high-density lipo-
protein cholesterol (HDL-C) and total cholesterol 
(TC); positive correlations were observed with tri-
glycerides (Tg), high sensitivity C-reactive protein 
(hsCRP) and homeostasis model assessment of in-
sulin resistance (HOMA-IR) (12,13). Plasma resistin 
has also been shown to be positively correlated 
with creatinine and was dependent on kidney 
function: Elevated resistin concentrations in chron-
ic kidney disease were associated with decreased 
glomerular filtration rate (GFR) (14). 
A strong link between circulating plasma resistin 
and both the presence and severity of CAD is 
known (6,15), although in some studies the link 
was lost after adjustment for traditional risk fac-
tors (12). Furthermore, resistin concentrations in-
crease with symptomatic severity of CAD (6,16,17), 
indicating that increased resistin concentrations 
may be a marker of myocardial ischemia and injury 
in ACS (6). Plasma resistin has been shown to be 
positively correlated with PBMC resistin mRNA in 
type 2 diabetes patients (18). However, the expres-
sion of resistin mRNA has not been described in 
CAD patients.
As PBMCs are one of the main sources of circulat-
ing plasma resistin, we sought to investigate 
whether PBMC resistin mRNA and its plasma pro-
tein concentration were changed in patients with 
presenting different CAD symptoms.
Material and methods
Subjects
This study was designed as an observational, case-
controlled study. Patients from the Institute for 
Cardiovascular Diseases at the Clinical Center of 
Serbia (Belgrade) who were admitted from Febru-
ary 2012 to January 2013 with requirements for 
coronary angiography were included in this study 
(77 patients, 38 male, 39 female). Indications for 
coronary angiography were stable angina; unsta-
ble angina; post-ischemic revascularization; AMI 
stratification post-AMI; undetermined chest pain 
origin; heart failure; valvulopathy; non-specific 
symptoms (asthenia, syncope and dyspnea); pre-
surgery for non-cardiac disease (19-21). The pres-
ence or absence of CAD was assessed using maxi-
mal luminal narrowing estimated by visual analysis 
using angiography. Clinically relevant CAD was 
considered when there was more than 50% steno-
sis in at least one major coronary artery (22). There 
were 30 patients without any evidence of CAD 
(CAD negative) and 47 CAD patients. 18 CAD pa-
tients were diagnosed with SAP. 29 CAD patients 
were diagnosed as having ACS including UAP and 
AMI diagnosed two weeks before blood was 
drawn. Criteria for SAP patients were the follow-
ing: a three month history of chronic, stable, ef-
fort-induced angina relieved by rest or nitroglycer-
ine; during exercise tests (experience of limiting 
angina and ST-segment depression of 0.1 mV com-
pared with rest (19). If patients had chest pain with 
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elevated troponin concentrations with or without 
ST-segment elevation seen on electrocardiogram 
(ECG) they were diagnosed as having AMI. Unsta-
ble angina (UA) was diagnosed in patients who 
were admitted with worsening angina, acute an-
gina after exercise within 3 weeks or renewed an-
gina at rest within 3 weeks (all without any evi-
dence of myocardial infarction as confirmed by 
subsequent serial ECG and myocardial biomarkers 
(20,21). Patients with diabetes mellitus (type I or II) 
and chronic renal failure were excluded from this 
study. Demographic data including age, body 
mass index (BMI), as well as data regarding medi-
cation used by patients were collected by a ques-
tionnaire.
The CG in this study consisted of 33 healthy blood 
donors (15 males and 18 females), who were se-
lected after thorough assessment of their health 
status, intima media thickness (IMT) measurement 
of both carotid arteries and review of their medical 
history to determine the presence or absence of 
cardiovascular disease. Demographic data includ-
ing age, BMI, as well as data regarding medication 
used by healthy blood donors, and family history 
indicating possible presence of absence of cardio-
vascular disease were collected by a questionnaire. 
Lipid profile was evaluated after the measurement 
of lipid parameters. Exclusion criteria for the CG 
were the presence of cardiovascular disease in 
family history, > 1 mm IMT in at least one carotid 
artery; hypertension (diastolic blood pressure ≥ 
90mm Hg and/or systolic blood pressure ≥ 140mm 
Hg) or use of any antihypertensive medication; un-
favorable lipid profile (according to Adult Treat-
ment Panel III guidelines – ATP III (23):  TC > 5.16 
mmol/L, LDL-C > 3.35 mmol/L, HDL-C < 1.03 
mmol/L, Tg > 1.70 mmol/L) or use of lipid lowering 
medication; presence of diabetes, glucose ≥ 6.1 
mmol/L, presence of obesity (BMI > 30 kg/m2). 
Along with plasma resistin and PBMC resistin 
mRNA in all subjects creatinine, lipid parameters 
(TC, HDL-C, LDL-C, Tg) and hsCRP were measured 
in order to assess their kidney function, lipid status 
and if low grade inflammation was present. Insulin 
resistance was evaluated by measuring glucose 
and insulin concentrations and calculation of the 
HOMA-IR index. Additionally, considering resistin’s 
connection to proinflammatory cytokine IL-6, 
plasma IL-6 as well as PBMC IL-6 mRNA expression 
was also determined. 
This study was conducted according to the guide-
lines laid down in Declaration of Helsinki and all 
procedures involving human subjects were ap-
proved by the ethical committee of Faculty of 
Pharmacy, University of Belgrade (approval num-
ber: 797/2) and School of Medicine, University of 
Belgrade (approval number: 29/11-15). All partici-
pants signed an informed consent before the en-
rolment.
Methods
Twelve hour fasting whole blood was drawn from 
all subjects, between 7 and 8 am. Blood was col-
lected into one serum and one EDTA containing 
tubes (BD Vacutainer®, New Jersey, USA). Serum 
and plasma were isolated after a 10 minute centrif-
ugation at 1000xg. Serum was analysed immedi-
ately after separation, while plasma was stored at 
-80°C for up to one year until analysis. PBMCs were 
immediately collected using Ficoll-Paque™ PLUS 
(GE Healthcare, Waukesha, Wisconsin, USA) rea-
gent according to the manufacturer’s protocol. 
Collected PBMCs were resuspended in TRIzol™ re-
agent (Ambion, Life technologies, Grand Island, 
New York), and total RNA was isolated according 
to the manufacturer’s protocol. 
The quantity of isolated RNA was assessed by 
measuring absorbance at 280 nm, while quality 
was determined by measuring absorbance ratios at 
260 nm and 280 nm (A260/280) as well as 260 nm 
and 230 nm (A260/230), to estimate protein and or-
ganic impurity, respectively. Samples with A260/280 
ratio greater than 1.8 and a A260/230 ratio greater 
than 2.4 were used. All absorbance measurements 
were performed on a Shimadzu 1800 UV-VIS spec-
trophotometer (Shimadzu, Kyoto, Japan). RNA in-
tegrity was evaluated by horizontal submarine 
electrophoresis (Hoefer, Inc. Holliston, Massachu-
setts, USA). The 18S and 28S ribosomal RNA (rRNA) 
bands were visualised with ethidium bromide on a 
MacroVue UV-25 trans-illuminator (Hoefer, Inc. 
Holliston, Massachusetts, USA) at 306 nm. Samples 
with clearly visible both subunits were used.
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All extracted RNAs were stored at -80 °C prior to 
reverse transcription (RT) reactions for up to one 
year. RT and real-time PCR experiments were car-
ried out on the 7500 Real-Time PCR System (Ap-
plied Biosystems, Foster City, CA, USA) using 
TaqMan® reagent-based chemistry. RT was per-
formed using high-capacity cDNA reverse tran-
scription kit (Applied Biosystems, Foster City, CA, 
USA) following the manufacturer’s instructions. 
Synthesised cDNAs were kept at -80 °C for up to 10 
days.
Quantitative real-time PCR was performed using 
TaqMan® 5’-nuclease gene expression assays (Ap-
plied Biosystems, Foster City, CA, USA) for human 
resistin gene (Hs00220767) and for IL-6 
(Hs00985639) gene, while beta actin (Hs01060665) 
was used as the housekeeping gene. All samples 
were pooled and five different dilutions of the 
pool were used to obtain a standard curve for 
each target gene and for a housekeeping gene. 5 
µL of cDNA was used as a template in a 15µL PCR 
reaction. The results were analysed in real-time 
mode using SDS Version 1.4.0.25 software. Data 
were expressed as a ratio between the target gene 
mRNA and the mRNA of the housekeeping gene: 
Normalised resistin mRNA= resistin mRNA/beta-
actin mRNA; normalised IL-6 mRNA = IL-6 mRNA/
beta-actin mRNA.
Creatinine, glucose and lipid parameters (TC, HDL-
C, LDL-C, Tg) were assayed from serum samples, by 
routine methods on a ILab 300+ analyser (Instru-
mentation Laboratory, Milan, Italy). hsCRP was 
measured from fresh serum samples, by a highly 
sensitive, latex particle-enhanced immunoassay 
(Roche Diagnostics, Mannheim, Germany). Intra-
assay coefficient of variations (CV) for human se-
rum were: CV (mean = 13.3 mg/L) =0.4%; CV (mean 
= 0.53 mg/L) = 1.6%, while inter-assay CVs were: 
CV (mean = 13.3 mg/L) = 2.1%; CV (mean = 0.53 
mg/L) = 8.4%, as indicated by the manufacturer. 
Fasting insulin concentrations were measured 
from fresh serum samples by an electro-chemilu-
minescence immunoassay method, on a 
COBAS®INTEGRA 400 plus analyser – Roche Diag-
nostics: intra-assay CV (mean = 6.36 μU/L) = 1.9%; 
inter-assay CV (mean = 6.36 μU/L) = 2.6%, as indi-
cated by the manufacturer. Insulin sensitivity was 
assessed using HOMA-IR [HOMA-IR = (fasting insu-
lin μU/mL x fasting glucose mmol/L)/22.5].
Resistin and IL-6 protein concentrations were 
measured from thawed plasma samples using an 
enzyme linked immunosorbent assay in all sub-
jects (ELISA, R&D systems, Wiesbaden, Germany) 
according to the manufacturer’s protocol. In order 
to assess intra-assay precision for resistin, 20 repli-
cates of pooled human plasma were run on one 
plate, CV (mean = 10.23 ng/mL) = 4.7%, while 10 
replicates on three different plates were run in 
three days in order to assess inter-assay precision, 
CV (mean = 10.43 ng/mL) = 8.4%. In order to assess 
intra-assay precision for IL-6, 20 replicates of 
pooled human plasma were run on one plate, CV 
(mean = 3.83 pg/mL) = 2.6 %, while 10 replicates 
on three different plates were run in three days in 
order to assess inter-assay precision, CV (mean = 
4.07 pg/mL) = 4.5%.  
Statistical analysis
All data were analysed using IBM® SPSS® Statistics 
version 22 software. Distribution of data was test-
ed using the Shapiro-Wilk test. All data are ex-
pressed as medians with interquartile ranges, 
while age is expressed as medians with min-max 
ranges. Groups were compared with the Kruskal-
Wallis and the Mann-Whitney U tests with Bonfer-
roni correction. Bonferroni adjustment was per-
formed by multiplying the nominal P values with 
the number of tests performed. Spearman correla-
tion analysis was used for data with skewed distri-
butions (24). Chi square analysis and Fisher 2x3 ex-
act tests were used for categorical variables. A P-
value of less than 0.05 was considered statistically 
significant.
Results
Baseline data and laboratory characteristics of 
controls and patients are shown in Table 1. Bonfer-
roni adjustment for all P values between groups 
was performed, and these values are further pre-
sented. All patients were significantly older than 
subjects in the CG. Serum creatinine was signifi-
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Number of subjects 33 30 18 29 /
Gender (M/%) 15/45% 12/40% 10/56% 16/55% 0.602
Age (years) 45 (27-60) 62 (32-80)a,*** 61 (52-74)a,*** 58 (38-82)a,*** <0 .001
BMI (kg/m2) 24.7 (22.6-27.2) 25.8 (24.4-28.0) 26.2 (25.7-28.5) 26.7 (23.5-28.3) 0.208
Creatinine (μmol/L) 86 (78-94) 68 (59-84)a,** 60 (58-85)a,* 74 (63-88)a,* 0 .001
Glucose (mmol/L) 5.1 (4.8-5.4) 5.2 (4.8-5.8) 5.1 (4.9-6.0) 5.5 (5.1-5.9) 0.102
TC (mmol/L) 4.80 (4.50-5.82) 4.72 (4.28-5.89) 4.61 (4.02-4.98) 4.53 (3.96-5.20) 0.256
LDL-C (mmol/L) 2.91 (2.52-3.54)c,** 3.07 (2.62-3.92)c,** 2.28 (2.17-2.60) 2.67 (2.35-3.50) 0 .003
HDL-C (mmol/L) 1.54 (1.35-1.82) 1.12 (0.96-1.45)a,*** 1.17 (1.07-1.38)a,*** 1.05 (0.90-1.30)a,*** <0 .001
Tg (mmol/L) 1.26 (0.99-1.64) 1.20 (1.02-1.52)c,**,b* 1.81 (1.39-2.26)a,* 1.66 (1.44-2.03) 0 .001
hsCRP (mg/L) 1.16 (0.61-1.87) 2.00 (1.2-5.6) 3.09 (0.87-5.35) 4.55 (2.09-8.95)a,** <0 .001
Insulin (μU/L) 8.37 (6.59-10.89)b,* 9.10 (6.21-13.65) 7.06 (6.82-13.44) 11.03 (9.15-19.68) 0 .010
HOMA-IR 1.89 (1.58-2.63)b,** 2.28 (1.32-2.99)b,* 2.74 (1.41-3.58) 3.43 (2.63-4.82) 0 .007
IL-6 (pg/mL) BDL 2.24 (0.79-3.29) 1.63 (1.00-5.58) 3.08 (1.21-8.82) 0.973
Normalised IL-6 mRNA 0.759 (0.462-1.138) 0.577 (0.297-0.860) 0.642 (0.445-0.736) 0.640 (0.407-0.938) 0.236
Resistin (ng/mL) 10.94 (7.79-13.01)b,** 11.58 (9.29-15.06)b,* 13.89 (10.46-15.06) 16.43 (11.76-23.41) <0 .001
Normalised resistin mRNA 0.725 (0.585-1.064) 0.695 (0.544-0.988) 0.774 (0.503-0.857) 0.684 (0.481-1.014) 0.988
Medication (with/without therapy)
ACE-inhibitors (N/total) / 20/10 16/2 18/11 0.143
Beta-blockers (N/total) / 18/12 10/8 22/7 0.273
Diuretics (N/total)† / 13/17 2/16 4/25 0 .015
Statins (N/total) / 8/22 6/12 15/14 0.133
Values are shown as medians with interquartile ranges (median, min-max range for age) and tested with Kruskal-Wallis test;
BMI - body mass index; TC - total cholesterol; LDL-C - low density lipoprotein cholesterol; HDL-C - high density lipoprotein cholesterol; 
Tg - triglycerides; hsCRP - high sensitivity C-reactive protein; HOMA-IR - homeostasis model assessment of insulin resistance; IL-6 - 
interleukin 6.
asignificantly different compared to healthy subjects; bsignificantly different compared to ACS group; csignificantly different 
compared to SAP group; *-P < 0.05; **-P < 0.01; ***-P < 0.001 after Bonferroni adjustment; BDL - below detection limit of the assay 
(< 0.7 pg/mL); †-P < 0.05 compared with Fisher 2x3 exact test.
Table 1. Clinical and laboratory characteristics of controls and patients
cantly higher in the CG compared to CAD negative 
(P = 0.006), SAP (P = 0.012) and ACS groups (P = 
0.024). LDL-C was lower in the SAP group com-
pared to the CG (P = 0.006) and CAD negative pa-
tients (P = 0.006). HDL-C was higher in the CG com-
pared to CAD negative (P < 0.001), SAP (P < 0.001) 
and ACS groups (P < 0.001). SAP and ACS groups 
had similar concentrations of Tg, both being high-
er than in the CAD negative group (P = 0.006 and 
P = 0.018, respectively), while SAP group had sig-
nificantly higher Tg concentrations than the CG (P 
= 0.024). HsCRP was lower in the CG compared to 
ACS group (P = 0.001). Insulin was higher in the 
ACS group compared to the CG group (P = 0.012). 
HOMA-IR index was significantly higher in the ACS 
group compared to the CG (P = 0.006) and the 
CAD negative group (P = 0.048). 
In contrast to that found in patients, IL-6 protein 
was present below the limit of detection (< 0.7 pg/
mL) in all control plasma samples. IL-6 mRNA did 
not show any significant difference between the 
groups (Table 1).
http://dx.doi.org/10.11613/BM.2015.025 Biochemia Medica 2015;25(2):242–51 
  247
Joksic J. et al. Resistin and coronary artery disease severity
Plasma resistin was significantly higher in the ACS 
group compared to the CG and CAD negative 
group (P = 0.001, P = 0.018, respectively, Table 1). 
However, resistin mRNA expression did not show 
any significant difference between any of the 
groups investigated (Table 1).
In patients plasma resistin correlated positively 
with creatinine and resistin mRNA but negatively 
with TC and HDL-C (Table 2). There was no correla-
tion with BMI, glucose, insulin or HOMA-IR index, 
IL-6 protein and hsCRP (Table 2). However, patients 
that were not taking statin therapy showed posi-
tive correlation of plasma resistin with hsCRP (Ta-
ble 2).
In patients resistin mRNA correlated positively 
with plasma resistin protein [this correlation was 
also observed in the CG (P = 0.046, ρ = 0.360)] and 
plasma IL-6, while negative correlation was ob-
served with HDL-C (Table 2). 
When plasma resistin was categorized into tertiles 
based on cut-off points of the entire patient distri-
bution, a high frequency of ACS patients were ob-
served in the third tertile. In the first and second 
tertiles CAD negative patients were abundant. The 
highest resistin tertile was accompanied by signifi-
cantly lower TC and HDL-C compared to the pa-
tients in the lowest tertile (Table 3). 
Discussion
For the first time PBMC resistin mRNA expression 
together with plasma resistin protein was investi-
gated in patients with CAD symptoms. We dem-
onstrated that plasma resistin was significantly el-
evated in the ACS group, compared to CG and 
CAD negative group. In contrast, resistin mRNA 
did not show any difference between the investi-
gated groups. In patients plasma resistin was posi-
tively associated with creatinine and resistin mRNA 
but negatively with TC and HDL-C. Resistin mRNA 
showed positive association with IL-6 protein but 
negative correlation with HDL-C. The highest plas-
ma resistin tertile included a high frequency of 
Parameter
Resistin protein Normalised resistin mRNA
ρ P ρ P
Age 0.214 0.062 0.026 0.827
BMI -0.202 0.082 -0.098 0.410
Creatinine 0.353 0 .002 0.166 0.156
Glucose -0.050 0.678 -0.086 0.482
TC -0.373 0 .001 -0.111 0.356
HDL-C -0.404 <0 .001 -0.257 0 .032
LDL-C -0.231 0.051 -0.093 0.442
Tg 0.048 0.684 -0.032 0.791
hsCRP 0.124 0.288* 0.164 0.165
Insulin 0.014 0.911 0.052 0.693
HOMA-IR -0.118 0.359 -0.086 0.512
IL-6 0.206 0.197 0.297 0.048
Normalised IL-6 mRNA -0.056 0.636 0.026 0.823
Resistin / / 0.305 0 .008
Normalised resistin mRNA 0.305 0 .008 / /
BMI - body mass index; TC - total cholesterol; LDL-C - low density lipoprotein cholesterol; HDL-C - high density lipoprotein cholesterol; 
Tg - triglycerides; hsCRP - high sensitivity C-reactive protein;  HOMA-IR - homeostasis model assessment of insulin resistance; IL-6 - 
interleukin 6.
*Significant when patients on statin therapy were excluded: P = 0.047, ρ = 0.295
Table 2. Correlations of plasma resistin and normalized resistin mRNA with other parameters in the patients group.
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(6 .17-10 .90 ng/mL)
N = 26
II tertile
(10 .91-16 .16 ng/mL)
N = 25
III tertile
(16 .17-38 .66 ng/mL)
N = 26
P
Patient subgroups § (SAP+CAD-/ACS) 19/7 19/6 9/17 0 .003
Age (years) 59 (37-80) 60 (32-75) 66 (38-82) 0.128
BMI (kg/m2) 26.7 (25.1-28.7) 25.8 (24.5-28.1) 26.6 (23.5-27.5) 0.550
Creatinine (μmol/L) 60 (54-78) 78 (60-87) 69 (64-97) 0.052
Glucose (mmol/L) 5.6 (4.9-6.0) 5.1 (4.7-5.5) 5.5 (5.1-5.9) 0.266
TC (mmol/L) 5.01 (4.53-5.97) 4.66 ( 4.14-5.73) 4.28 (3.68-4.81)* 0 .033
HDL-C (mmol/L) 1.32 (1.08-1.45) 1.15 (0.90-1.47) 0.97 (0.87-1.20)** 0 .012
LDL-C (mmol/L) 2.96 (2.44-4.07) 2.95 (2.40-3.70) 2.64 (2.21-3.01) 0.243
Tg (mmol/L) 1.39 (1.22-2.31) 1.46 (1.04-1.76) 1.64 (1.20-1.96) 0.501
hsCRP (mg/L) 2.40 (1.56-5.35) 2.37 (0.82-6.40) 5.31 (2.05-9.75) 0.222
Insulin (μU/L) 9.20 (7.04-11.06) 13.44 (6.82-16.57) 10.71 (6.05-16.50) 0.386
HOMA-IR 2.51 (2.20-3.20) 2.98 (1.52-3.73) 2.65 (1.33-3.96) 0.826
IL-6 (pg/mL) 1,83 (1,42-4,75) 2,46 (1,16-3,81) 7,25 (1,36-9,59) 0.288
Normalised IL-6 mRNA 0.642 (0.408-0.792) 0.538 (0.323-0.844) 0.543 (0.330-0.986) 0.642
Normalised resistin mRNA 0.648 (0.481-0.786) 0.731 (0.578-0.949) 0.834 (0.534-1.351) 0 .047
Values are shown as medians with interquartile ranges (median, min-max range for age) and tested with Kruskal-Wallis test.
BMI - body mass index; TC - total cholesterol; LDL-C - low density lipoprotein cholesterol; HDL-C - high density lipoprotein cholesterol; 
Tg - triglycerides; hsCRP - high sensitivity C-reactive protein; HOMA-IR - homeostasis model assessment of insulin resistance; IL-6 - 
interleukin 6; CAD - coronary artery disease negative patients; SAP - stabile angina pectoris patients; ACS - acute coronary syndrome 
patients.
*significantly different compared to the I tertile: P = 0.027 after Bonferroni adjustment.
**significantly different compared to the I tertile: P = 0.006 after Bonferroni adjustment.
§ -values were analysed by Chi-square test.
Table 3. Anthropometric, laboratory and gene expression data according to plasma resistin concentration tertiles in patients.
ACS patients, but lower values of TC and HDL-C 
compared to patients in the lowest tertile.
Several in vitro experiments have indicated that re-
sistin plays an important role in endothelial dys-
function, considered as one of the earliest stages 
of atherosclerosis development (6). Qiao and co-
workers found that resistin plasma concentrations 
were higher in AMI, UAP and SAP patients com-
pared to healthy subjects, even without adjust-
ment for GFR or age (16). Lubos and colleagues 
also observed higher resistin plasma concentra-
tions in ACS patients and indicated a potential use 
of resistin as a diagnostic marker. However, plasma 
resistin concentrations were not associated with 
future cardiovascular outcome (12,17). Herein we 
have shown that plasma resistin is strongly associ-
ated with serum creatinine, which is in agreement 
with the findings of other authors (14) and sug-
gests that its metabolism is strongly dependent of 
kidney function.
Our study has revealed a positive association be-
tween PBMC resistin mRNA expression and circu-
lating resistin in both the CG and CAD patients. 
Mezaghi and colleagues found a positive associa-
tion between plasma resistin and PBMC resistin 
mRNA in type 2 diabetes patients (18). Tsiotra and 
co-workers reported the same observation be-
tween resistin mRNA expression from human pe-
ripheral monocyte enriched mononuclear cells 
and circulating resistin in type 2 diabetic women 
(25). However, PBMC resistin mRNA expression was 
similar between the examined study groups. 
http://dx.doi.org/10.11613/BM.2015.025 Biochemia Medica 2015;25(2):242–51 
  249
Joksic J. et al. Resistin and coronary artery disease severity
While the contribution by PBMCs to the resistin 
plasma concentrations is not to be underestimat-
ed, other factors beside kidney function can con-
tribute to its final plasma concentrations. Resistin 
is secreted from macrophages, in atheroma, local-
ly and abundantly where it exerts its effects within 
atherosclerotic lesions in a paracrine manner (6). 
Furthermore, it is commonly believed that activa-
tion of inflammatory cells in culprit stenosis is the 
cause of coronary instability in all patients (2). Ad-
ditionally, some papers reported resistin’s possible 
contribution to atherothrombosis by promoting 
tissue factor expression, thus representing an ef-
fector molecule able to induce a pro-thrombotic 
phenotype in cells present in the vessel wall (6). In 
such a way resistin could contribute to complex in-
travascular inflammatory and pro-thrombotic re-
sponses which are the major components leading 
to dynamic instability of a coronary atherosclerotic 
plaque, regarded as the foundation for the devel-
opment of the clinical syndromes including UAP 
and AMI (2). This could explain why the highest re-
sistin plasma concentrations, without PBMC resist-
in gene expression differences were observed in 
ACS patients: During plaque destabilisation, which 
takes its course in UAP and AMI, resistin protein 
could be additionally released from the plaque it-
self (6).
Other studies have examined connections be-
tween plasma resistin and HDL-C concentrations 
(12,13). We have shown for the first time that not 
only plasma resistin but also its PBMC mRNA are 
inversely related to HDL-C. Furthermore, patients 
with the highest plasma resistin, possess a more 
pro-atherogenic lipid status: HDL-C concentrations 
were the lowest in that group. In line with previ-
ously reported results (13), plasma resistin was 
negatively associated with TC and TC concentra-
tions were the lowest in patients with the highest 
plasma resistin, which could be a consequence of 
the negative association observed with HDL-C 
concentrations. Sato and co-workers reported that 
mouse resistin protein can attenuate ApoA1 mRNA 
expression in the liver, which could be the cause of 
lower HDL-C concentrations seen in mice treated 
with resistin adenovirus (26). However, one should 
bear in mind the discrepancies that exist between 
human and mouse resistin proteins (3-5). The ex-
act relationship between resistin, both plasma 
protein and PBMC mRNA expression, and HDL-C in 
humans remains to be clarified. 
In other reports resistin has been shown to be 
positively associated with markers of inflamma-
tion, such as hsCRP (12,16,17) and IL-6 protein (27). 
We observed significant positive correlation be-
tween resistin and hsCRP, but only when exclud-
ing subjects that were taking statin therapy. 
Namely, statins are known to exert pleiotropic an-
ti-inflammatory effects via HMG-CoA reductase-
independent pathways. In particular simvastatin 
inhibits hsCRP-induced resistin expression in cul-
tured human PBMCs via the mevalonate-GGPP 
pathway (28). This could explain why only patients 
that were not on lipid lowering therapy retained 
this correlation. However, we were not able to 
show that resistin was positively correlated with 
plasma IL-6. On the other hand, PBMC resistin 
mRNA expression positively correlated with plas-
ma IL-6. This could be due to the fact that not only 
can resistin stimulate IL-6 expression, but IL-6 can 
stimulate resistin expression in PBMCs (7,8). Ander-
son and colleagues observed an increase in both 
IL-6 protein and PBMC IL-6 mRNA expression in 
AMI patients (29). We failed to confirm this, most 
likely due to different study design. 
Some limitations within this study should be men-
tioned. First, we had small study group sizes. Our 
findings should be confirmed using larger study 
groups. Second, patients were older than the 
healthy subjects. Third, lipid parameters were 
measured over a rather short time after acute cor-
onary events. Finally, all patients received some 
form of therapy (lipid lowering or anti-hyperten-
sive medications), which could have influenced 
our results (6,30). 
Conclusion
In this study we have observed significant increase 
of plasma resistin in patients with ACS compared 
to CG and CAD negative patients. Despite no 
change in PBMC resistin mRNA in different disease 
conditions a positive association between resistin 
mRNA and resistin plasma protein was evident. 
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Furthermore, a positive association between plas-
ma resistin and serum creatinine concentrations 
was demonstrated. Both plasma resistin and PBMC 
resistin mRNA were negatively associated with 
plasma HDL-C. 
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